BRCA1 and cancer: Treatment with a PARPi in BRCA1 mutant cancers causes diminished heterodimerization with BRCA1 associated ring domain 1 (BARD1) and has been shown to decrease PAR formation and recruitment of BRCA1/BARD1 complex to the site of DNA damage.